Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

Pharmacopeia Advances and Expands Internal Pipeline as DARA Program Enters

Phase 2 Clinical Development and New SARM Program is Added

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP) today announced results for the quarter and nine months ended September 30, 2007, and highlighted several important developments in its therapeutic programs and corporate milestones achieved since the beginning of the quarter.

During the third quarter of 2007:

-- Pharmacopeia announced the initiation of a Phase 2a hypertension

clinical trial for PS433540, an unpartnered product candidate from its

DARA program, that is both an angiotensin receptor blocker (ARB) and an

endothelin receptor antagonist (ERA). The trial was initiated less

than one year after IND submission and approximately six months ahead

of schedule.

Also during the quarter, the company announced positive results from

multiple Phase 1 clinical studies for PS433540. These Phase 1 findings

included:

-- PS433540 demonstrated its ability to block the increase in blood

pressure induced by administration of angiotensin II (AII) to

healthy volunteers. Numerous similar studies with other agents that

block the renin-angiotensin system support that this result is a

strong indication that PS433540 can be expected to lower blood

pressure in hypertensive patients. This Phase 1 study showed that

all doses of PS433540, compared with placebo, produced a

statistically significant (p<0.01) inhibition of the expected AII-

induced increase in blood pressure. Additionally, the findings

showed that the 250 mg and 500 mg doses of PS433540 were at least as

effective in blocking the AII response as irbesartan, a leading

angiotensin receptor blocker that is approved for th
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... deliveries a possible cause, study suggests, , , WEDNESDAY, Jan. ... of women giving birth experience severe complications, a new ... between 1998 and 2005. , Problems such as blood ... need for blood transfusions rose from 0.64 percent in ...
... 2009) The American Gastroenterological Association (AGA) Institute journal, ... journal with the most impact on the field of ... Science Indicators data by Thompson Reuters. This impact was ... any clinical medical journal. The current citation record for ...
... study appearing in The Prostate has found that ... as MV-CEA, may prove to be an effective treatment for ... type of treatment, called virotherapy, can effectively infect, replicate in ... a leading cause death among males in the western world. ...
... AUSTIN, Texas, Jan. 21 Alliance Tech ... measurement utilizing RFID, announced today that Carestream ... measurement technologies to identify additional lead opportunities ... North America (RSNA) conference held in Chicago ...
... and Germany pledge critically needed funds and urge ... crippling childhood diseaseSAN DIEGO, Jan. 21 Rotary ... the British and German governments today committed more ... polio, a crippling and sometimes fatal disease that ...
... and services, announced that Maggie O,Hara, IVANS group vice president of ... finalist in the fifth annual Women of Innovation awards program hosted ... ... (Vocus) January 21, 2009 -- IVANS, Inc. , a leading ...
Cached Medicine News:Health News:Severe Obstetric Complications on the Increase 2Health News:Severe Obstetric Complications on the Increase 3Health News:Clinical Gastroenterology and Hepatology most influential journal in field of clinical medicine 2Health News:Measles virus may be effective prostate cancer treatment 2Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 2Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 3Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 2Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 3Health News:Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication 4Health News:Maggie O'Hara Named as a Finalist in Connecticut Technology Council's Women of Innovation Awards Program 2Health News:Maggie O'Hara Named as a Finalist in Connecticut Technology Council's Women of Innovation Awards Program 3
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
... system features an advanced design that accommodates ... system gives surgeons the flexibility to easily ... Flexibility is built-in to every aspect of ... innovative Secure-TwistTM anti-migration system to the screw ...
... The SC-Acufix anterior cervical plate system is ... patented, integrated swivel, which provides for consistent, ... prevents bone screw disengagement or backout. This ... secondary locking screw. Simply implant your screws ...
Medicine Products: